SSA
ACRS icon

Schonfeld Strategic Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-127,592
Closed -$195K – 1992
2025
Q1 		$195K Sell
127,592
-4,303
-3% -$9.18K ﹤0.01% 1947
2024
Q4 		$327K Buy
+131,895
New +$328K ﹤0.01% 1578
2024
Q3 		– Sell
-35,300
Closed -$38.8K – 1999
2024
Q2 		$38.8K Buy
+35,300
New +$41.5K ﹤0.01% 1958
2023
Q4 		– Sell
-269,746
Closed -$1.85M – 1833
2023
Q3 		$1.85M Sell
269,746
-184,665
-41% -$1.58M 0.01% 852
2023
Q2 		$4.71M Sell
454,411
-115,832
-20% -$1.05M 0.04% 504
2023
Q1 		$4.61M Buy
570,243
+158,005
+38% +$2.01M 0.04% 465
2022
Q4 		$6.49M Buy
412,238
+12,078
+3% +$194K 0.05% 409
2022
Q3 		$6.3M Sell
400,160
-36,100
-8% -$569K 0.05% 454
2022
Q2 		$6.09M Sell
436,260
-36,500
-8% -$512K 0.06% 416
2022
Q1 		$8.15M Sell
472,760
-17,700
-4% -$241K 0.07% 313
2021
Q4 		$7.13M Sell
490,460
-22,415
-4% -$340K 0.06% 370
2021
Q3 		$9.23M Buy
512,875
+258,531
+102% +$4.14M 0.1% 277
2021
Q2 		$4.47M Sell
254,344
-113,048
-31% -$2.57M 0.05% 490
2021
Q1 		$9.26M Buy
367,392
+60,492
+20% +$1.18M 0.11% 246
2020
Q4 		$1.99M Buy
306,900
+57,700
+23% +$243K 0.03% 598
2020
Q3 		$641K Buy
249,200
+53,100
+27% +$119K 0.01% 835
2020
Q2 		$318K Buy
196,100
+173,834
+781% +$233K 0.01% 971
2020
Q1 		$23K Buy
+22,266
New +$30.3K ﹤0.01% 1072
2018
Q4 		– Sell
-65,000
Closed -$944K – 1034
2018
Q3 		$944K Sell
65,000
-100
-0.2% -$1.71K 0.04% 438
2018
Q2 		$1.3M Buy
65,100
+19,272
+42% +$356K 0.07% 348
2018
Q1 		$804K Buy
+45,828
New +$971K 0.06% 376
2017
Q3 		– Sell
-40,000
Closed -$1.08M – 569
2017
Q2 		$1.08M Sell
40,000
-8,277
-17% -$225K 0.11% 262
2017
Q1 		$1.44M Buy
+48,277
New +$1.39M 0.14% 199

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Schonfeld Strategic Advisors's ACRS Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 127,592 shares — an estimated $195K sold.

Schonfeld Strategic Advisors first reported a position in ACRS in Q1 2017 and held it in 23 quarters. The position peaked at $9.26M in Q1 2021. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

  • Schonfeld Strategic Advisors reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 127,592 Aclaris Therapeutics shares in Q2 2025, an estimated $195K.
  • Schonfeld Strategic Advisors first reported a position in Aclaris Therapeutics in Q1 2017 and held it in 23 quarters.
  • Schonfeld Strategic Advisors's Aclaris Therapeutics position peaked at $9.26M in Q1 2021.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.